Novartis AG (VTX:NOVN) has been given an average rating of “Hold” by the fifteen analysts that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and seven have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is CHF 85.70.

NOVN has been the topic of several analyst reports. Goldman Sachs Group, Inc. (The) set a CHF 80 price target on shares of Novartis AG and gave the stock a “neutral” rating in a research note on Tuesday, October 17th. Morgan Stanley set a CHF 88 price target on shares of Novartis AG and gave the stock a “buy” rating in a research note on Wednesday, July 26th. Berenberg Bank set a CHF 85 price target on shares of Novartis AG and gave the stock a “neutral” rating in a research note on Friday, July 14th. Deutsche Bank AG set a CHF 80 price target on shares of Novartis AG and gave the stock a “neutral” rating in a research note on Friday, July 7th. Finally, Sanford C. Bernstein set a CHF 94 price target on shares of Novartis AG and gave the stock a “buy” rating in a research note on Tuesday, July 18th.

TRADEMARK VIOLATION WARNING: “Novartis AG (NOVN) Receives Consensus Rating of “Hold” from Analysts” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/10/26/novartis-ag-novn-receives-consensus-rating-of-hold-from-analysts.html.

Shares of Novartis AG (VTX:NOVN) opened at 80.70 on Thursday. Novartis AG has a one year low of CHK 67.40 and a one year high of CHK 85.40. The firm’s 50-day moving average is CHK 83.19 and its 200-day moving average is CHK 80.22. The company has a market cap of CHK 189.07 billion and a PE ratio of 29.46.

Novartis AG Company Profile

Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.

Analyst Recommendations for Novartis AG (VTX:NOVN)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.